Cartesian Therapeutics (RNAC) Equity Ratio (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Equity Ratio for 11 consecutive years, with 0.43 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio fell 2623.82% to 0.43 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.43, a 2623.82% decrease, with the full-year FY2025 number at 0.43, down 2623.82% from a year prior.
- Equity Ratio was 0.43 for Q4 2025 at Cartesian Therapeutics, down from 0.1 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.57 in Q3 2023 to a low of 1.44 in Q4 2023.
- A 5-year average of 0.03 and a median of 0.01 in 2025 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: soared 2137.2% in 2022, then crashed 5923.46% in 2025.
- Cartesian Therapeutics' Equity Ratio stood at 0.14 in 2021, then soared by 301.55% to 0.57 in 2022, then crashed by 355.12% to 1.44 in 2023, then surged by 98.92% to 0.02 in 2024, then crashed by 2623.82% to 0.43 in 2025.
- Per Business Quant, the three most recent readings for RNAC's Equity Ratio are 0.43 (Q4 2025), 0.1 (Q3 2025), and 0.01 (Q2 2025).